ZAS Corporation recently organized a series of training sessions across multiple hospitals, engaging ICU nurses on the safe and effective use of noradrenaline in critical care settings. The program focused on practical guidance, updated protocols, and real-world application to support better patient outcomes. Through these interactive sessions, ZAS continues its commitment to enhancing clinical excellence and partnering with healthcare professionals who play a vital role in saving lives every day.
More Releases
ZAS Corporation Participates in Anesthesia Day 2025, Strengthening Commitment to Patient Care
https://www.facebook.com/share/v/1a9fjSn8TH
ZAS Corporation was privileged to participate in the Anesthesia...
|
25 Feb, 2026
ZAS Corporation Launches DECA® Surgical Glove Series, A New Era in Surgical Excellence
ZAS Corporation proudly announces the official launch of its DECA® series of sterile surgical gloves,...
|
16 Sep, 2025
ZAS Corporation Strengthens Partnership with Celltrion Korea
ZAS Corporation recently held a strategic business overview meeting with its esteemed global partner,...
|
16 Sep, 2025
ZAS Industries Launches Advanced Wound Care Products from Pharmaplast.
ZAS Industries proudly announces the launch of a new range of premium wound care products from Pharmaplast,...
|
16 Sep, 2025
ZAS Corporation & BIRDEM General Hospital Introduce Advanced Biosimilar Therapies in Rheumatology Care
ZAS Corporation is proud to collaborate with the Rheumatology Department of BIRDEM General Hospital to...
|
16 Sep, 2025
ZAS Corporation Highlights Urovaxom® at OGSB International Scientific Conference 2025
ZAS Corporation Ltd. was honored to take part in the 33rd International Scientific Conference & 51st...
|
16 Sep, 2025
ZAS Corporation Hosts CME on Advancing Psoriasis Care with Adalimumab
ZAS Corporation’s Dermatology Division recently organized a Continuing Medical Education (CME) program...
|
16 Sep, 2025
ZAS Corporation Empowers ICU Nurses with Noradrenaline Best Practices Training
ZAS Corporation recently organized a series of training sessions across multiple hospitals, engaging...
|
16 Sep, 2025
ZAS Onco & MOSB Host Scientific Seminar on Recent Advances in Bevacizumab Therapy
ZAS Onco, a division of ZAS Corporation Ltd., in collaboration with the Medical Oncology Society of Bangladesh...
|
03 Jun, 2025
ZAS Corporation Joins Aqvida GmbH in Celebrating 20 Years of Oncology Excellence in Germany
Hamburg & Dassow, Germany | 14–17 May 2025ZAS Corporation proudly participated in the 20th anniversary...
|
22 May, 2025